FDA Brief

Warning letters Drugs

FDA warning letter to

Mahita, LLC dba PushMyCart

High riskIssued Aug 19, 2021Posted Aug 20, 2021Center for Drug Evaluation and Research | CDER

FDA and FTC warn Mahita/PushMyCart over unapproved Ayurvedic/homeopathic COVID-19 treatment claims.

What happened

FDA reviewed the website on August 2, 2021, and FTC reviewed it on August 16, 2021; FDA also reviewed the company’s Facebook page and Amazon storefront. FDA found the company offered Patanjali Coronil Kit, arsenic album dilutions, and Balarishtam products for sale in the U.S. with claims that they mitigate, prevent, treat, diagnose, or cure COVID-19. FDA called them unapproved new drugs and misbranded drugs.

What FDA found

  1. The company sold products as drugs for COVID-19 without FDA approval.

    FD&C Act section 505(a), 21 U.S.C. § 355(a)
  2. The products’ labeling and promotions misbranded them.

    FD&C Act section 502, 21 U.S.C. § 352
  3. The company introduced or delivered these products into interstate commerce, which is prohibited.

    FD&C Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)
  4. The company advertised that the products can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. 41 et seq.

What FDA wants

FDA tells the company to immediately stop selling the unapproved COVID-19 products and, within 48 hours, email FDA with the steps taken and documentation to prevent repeat violations. FTC also requires a 48-hour email certifying that the unsubstantiated claims have stopped.

Who should pay attention

  • online sellers of Ayurvedic or homeopathic products
  • marketplaces hosting third-party product listings
  • companies making disease-treatment claims in ads

This is a summary. Read the original letter on fda.gov.

Mahita, LLC dba PushMyCart's FDA history

  1. Mahita LLC dba PushMyCart

    FDA told online seller PushMyCart its website and Facebook posts sell unapproved drugs claiming to treat measles, cancer, diabetes and Parkinson's.

    High risk

Full company page

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk